Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07721623 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Efficacy of Carbitocin in Reduction of Blood Loss During Myomectomy

StatusNot Yet Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Minor Study First Submitted
The uterine fibroids are the most common benign tumors found in the female reproductive system. Uterine fibroids commonly cause heavy menstrual periods. The prevalence of uterine fibroids is significantly affecting up to 70-80% of women by the age of 50, with an inconsistent impact on women of African origin. Carbitocin is a synthetic analogue of oxytocin which has a longer half-life than oxytocin. A Cochrane review and meta-analysis studies found that carbitocin reduced the use of additional uterotonics and transfusion. However, few of these studies was done during myomectomy.
Trial Details
NCT Number NCT07721623
Lead Sponsor Alex Ekwueme Federal University Teaching Hospital
Conditions
(from sponsor)
Blood Loss, Surgical
Related terms Blood Loss, Surgical, Hemorrhage
Enrollment 900 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov